title: Minister rules out use of Avastin over Lucentis for wet AMD.
authors.affiliation: The BMJ.
authors.forename: Zosia
authors.initials: Z
authors.lastname: Kmietowicz
mesh_terms: D020533:Angiogenesis Inhibitors / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000191:economics; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D033161:Government Regulation; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D056687:Off-Label Use; D000069579:Ranibizumab; D018570:Risk Assessment; D006113:United Kingdom
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab